https://news.medxy.ai/zh/pcos-pmos-health-2/Medxy AIzh2026-08-31T09:07:48-07:00从PCOS到PMOS：重塑对女性生殖健康的认识与照护 https://news.medxy.ai/ja/pcos-to-pmos/Medxy AIja2026-08-31T09:07:23-07:00PCOSからPMOSへ：女性の生殖医療における理解とケアの転換 https://news.medxy.ai/vi/pcos-pmos-health/Medxy AIvi2026-08-31T09:06:53-07:00Từ PCOS đến PMOS: Thay đổi cách hiểu và chăm sóc sức khỏe sinh sản nữ giới https://news.medxy.ai/zh/long-covid-pregnancy-2/Medxy AIzh2026-08-31T09:05:50-07:00妊娠期长新冠：早产与高血压并发症风险评估 https://news.medxy.ai/ja/long-covid-pregnancy-impact/Medxy AIja2026-08-31T09:05:32-07:00妊娠中のLong COVID：早産と妊娠高血圧症候群への影響を検証 https://news.medxy.ai/vi/long-covid-pregnancy/Medxy AIvi2026-08-31T09:05:11-07:00Long COVID trong thai kỳ: Đánh giá nguy cơ sinh non và rối loạn tăng huyết áp https://news.medxy.ai/zh/early-pregnancy-abnormalities/Medxy AIzh2026-08-31T08:34:53-07:00孕早期胎儿异常检出再升级：StaFFAUS方案在超声筛查中的表现 https://news.medxy.ai/ja/early-fetal-abnormalities/Medxy AIja2026-08-31T08:34:37-07:00第一三半期超音波で胎児異常の早期発見を強化：StaFFAUS プロトコルの検証 https://news.medxy.ai/vi/early-fetal-anomaly-detection/Medxy AIvi2026-08-31T08:34:12-07:00Tăng cường phát hiện sớm bất thường thai nhi: Đánh giá quy trình StaFFAUS trong sàng lọc siêu âm tam cá nguyệt thứ nhất https://news.medxy.ai/zh/risk-assessment-chronic-liver-disease/Medxy AIzh2026-08-31T08:31:35-07:00从压力指标到个体化预后：重塑进展期慢性肝病的风险评估 https://news.medxy.ai/ja/68941-2/Medxy AIja2026-08-31T08:31:13-07:00ストレスマーカーから個別化された予後予測へ：進行性慢性肝疾患におけるリスク評価の再構築 https://news.medxy.ai/vi/personalized-risk-assessment/Medxy AIvi2026-08-31T08:30:51-07:00Từ các chỉ số áp lực đến tiên lượng cá thể hóa: Cách mạng hóa đánh giá nguy cơ trong bệnh gan mạn tiến triển https://news.medxy.ai/global-insights-on-implantable-cardioverter-defibrillators-in-high-risk-hypertrophic-cardiomyopathy-efficacy-and-outcomes/Medxy AIen2026-08-31T02:43:00-07:00Global Insights on Implantable Cardioverter-Defibrillators in High-Risk Hypertrophic Cardiomyopathy: Efficacy and Outcomes https://news.medxy.ai/targeting-the-ca19-9-glycan-a-promising-car-t-cell-therapy-for-pancreatic-and-gastrointestinal-cancers/Medxy AIen2026-08-30T15:28:42-07:00Targeting the CA19-9 Glycan: A Promising CAR T Cell Therapy for Pancreatic and Gastrointestinal Cancers https://news.medxy.ai/recent-mechanical-venous-thrombosis-risk-factors-and-their-role-in-young-onset-cryptogenic-ischemic-stroke/Medxy AIen2026-08-30T15:28:03-07:00Recent Mechanical Venous Thrombosis Risk Factors and Their Role in Young-Onset Cryptogenic Ischemic Stroke https://news.medxy.ai/rnf213-p-r4810k-variant-a-novel-independent-genetic-risk-factor-for-extracranial-carotid-artery-disease/Medxy AIen2026-08-30T15:26:21-07:00RNF213 p.R4810K Variant: A Novel Independent Genetic Risk Factor for Extracranial Carotid Artery Disease https://news.medxy.ai/unraveling-white-matter-hyperintensities-distinct-lesion-subtypes-reveal-diverse-clinical-implications-beyond-location/Medxy AIen2026-08-30T15:24:43-07:00Unraveling White Matter Hyperintensities: Distinct Lesion Subtypes Reveal Diverse Clinical Implications Beyond Location https://news.medxy.ai/severe-parsonage-turner-syndrome-vs-traumatic-brachial-plexopathy-insights-into-motor-recovery-and-treatment-outcomes/Medxy AIen2026-08-30T15:22:55-07:00Severe Parsonage-Turner Syndrome vs. Traumatic Brachial Plexopathy: Insights into Motor Recovery and Treatment Outcomes https://news.medxy.ai/refining-risk-stratification-in-indeterminate-thyroid-nodules-the-role-of-afirma-xpression-atlas-alteration-status/Medxy AIen2026-08-30T15:20:59-07:00Refining Risk Stratification in Indeterminate Thyroid Nodules: The Role of Afirma Xpression Atlas Alteration Status https://news.medxy.ai/rotavirus-vaccination-and-type-1-diabetes-incidence-insights-from-a-norwegian-population-based-natural-experiment/Medxy AIen2026-08-30T15:19:13-07:00Rotavirus Vaccination and Type 1 Diabetes Incidence: Insights from a Norwegian Population-Based Natural Experiment https://news.medxy.ai/enhanced-diagnosis-of-primary-aldosteronism-comparing-lc-ms-ms-and-immunoassay-for-urinary-aldosterone-measurement/Medxy AIen2026-08-30T15:17:21-07:00Enhanced Diagnosis of Primary Aldosteronism: Comparing LC-MS/MS and Immunoassay for Urinary Aldosterone Measurement https://news.medxy.ai/comparative-impacts-of-semaglutide-and-bariatric-surgery-on-hepatic-steatosis-and-fibrosis-in-obese-patients-with-masld/Medxy AIen2026-08-30T15:15:30-07:00Comparative Impacts of Semaglutide and Bariatric Surgery on Hepatic Steatosis and Fibrosis in Obese Patients with MASLD https://news.medxy.ai/impact-of-the-dash4d-diet-on-glycemic-biomarkers-in-adults-with-type-2-diabetes-insights-from-a-randomized-controlled-feeding-trial/Medxy AIen2026-08-30T15:13:55-07:00Impact of the DASH4D Diet on Glycemic Biomarkers in Adults with Type 2 Diabetes: Insights from a Randomized Controlled Feeding Trial https://news.medxy.ai/optimizing-capillary-ketone-testing-frequency-to-predict-short-term-diabetic-ketoacidosis-risk-in-type-1-diabetes/Medxy AIen2026-08-30T15:12:11-07:00Optimizing Capillary Ketone Testing Frequency to Predict Short-Term Diabetic Ketoacidosis Risk in Type 1 Diabetes https://news.medxy.ai/revolutionizing-aortic-stenosis-screening-ai-enabled-focused-cardiac-ultrasound-with-novice-operators/Medxy AIen2026-08-30T15:10:31-07:00Revolutionizing Aortic Stenosis Screening: AI-Enabled Focused Cardiac Ultrasound with Novice Operators https://news.medxy.ai/advancing-prognostication-in-transthyretin-amyloid-cardiomyopathy-a-machine-learning-risk-prediction-model/Medxy AIen2026-08-30T15:09:01-07:00Advancing Prognostication in Transthyretin Amyloid Cardiomyopathy: A Machine Learning Risk Prediction Model https://news.medxy.ai/evolving-impact-of-implantable-cardioverter-defibrillators-on-mortality-post-myocardial-infarction-insights-from-the-profid-study/Medxy AIen2026-08-30T15:07:15-07:00Evolving Impact of Implantable Cardioverter-Defibrillators on Mortality Post-Myocardial Infarction: Insights from the PROFID Study https://news.medxy.ai/bridging-the-gap-esc-prevention-and-cardiac-rehabilitation-recommendations-and-what-euroaspire-vi-reveals-about-reality-in-europe/Medxy AIen2026-08-30T15:04:50-07:00Bridging the Gap: ESC Prevention and Cardiac Rehabilitation Recommendations and What EUROASPIRE VI Reveals About Reality in Europe https://news.medxy.ai/low-normal-hemoglobin-concentrations-and-clinical-outcomes-in-heart-failure-rethinking-who-anemia-thresholds/Medxy AIen2026-08-30T15:02:36-07:00Low-Normal Hemoglobin Concentrations and Clinical Outcomes in Heart Failure: Rethinking WHO Anemia Thresholds https://news.medxy.ai/sustained-cardiovascular-protection-with-evolocumab-in-patients-without-prior-mi-or-stroke-insights-from-the-vesalius-cv-trial/Medxy AIen2026-08-30T15:00:39-07:00Sustained Cardiovascular Protection With Evolocumab in Patients Without Prior MI or Stroke: Insights From the VESALIUS-CV Trial https://news.medxy.ai/low-ventricular-chamber-stiffness-as-a-marker-of-high-risk-eccentric-remodeling-in-fontan-circulation-insights-from-the-force-registry/Medxy AIen2026-08-30T14:58:51-07:00Low Ventricular Chamber Stiffness as a Marker of High-Risk Eccentric Remodeling in Fontan Circulation: Insights from the FORCE Registry https://news.medxy.ai/sustained-cardiovascular-benefits-of-intensive-blood-pressure-management-led-by-nonphysician-providers-7-year-follow-up-of-the-crhcp-trial/Medxy AIen2026-08-30T14:57:06-07:00Sustained Cardiovascular Benefits of Intensive Blood Pressure Management Led by Nonphysician Providers: 7-Year Follow-Up of the CRHCP Trial https://news.medxy.ai/cancer-biologics-utilization-after-biosimilar-entry-and-financial-implications-for-payers-and-patients/Medxy AIen2026-08-30T14:55:37-07:00Cancer Biologics Utilization After Biosimilar Entry and Financial Implications For Payers and Patients https://news.medxy.ai/zh/beyond-cirrhosis-alpha1-antitrypsin-deficiency/Medxy AIzh2026-08-30T08:33:09-07:00超越肝硬化：解读 Alpha-1 抗胰蛋白酶缺乏症不同基因型相关的主要不良肝脏结局 https://news.medxy.ai/vi/il-12p40-il-18-roles/Medxy AIvi2026-08-30T08:33:06-07:00Vai trò trái ngược của IL-12p40 và IL-18 trong bệnh ghép chống chủ mạn tính xơ hóa nặng: hàm ý đối với miễn dịch và kết cục sau ghép https://news.medxy.ai/ja/alpha-1-liver-disease/Medxy AIja2026-08-30T08:32:53-07:00肝硬変だけではない：Alpha-1 antitrypsin deficiency遺伝子型にみる主要有害肝アウトカムの全体像 https://news.medxy.ai/vi/beyond-cirrhosis/Medxy AIvi2026-08-30T08:32:34-07:00Vượt ra ngoài xơ gan: Hiểu về các biến cố gan bất lợi chính trong các kiểu gen thiếu hụt Alpha-1 antitrypsin https://news.medxy.ai/zh/car-t-therapy/Medxy AIzh2026-08-30T08:29:51-07:00靶向 CA19-9 糖链：胰腺癌与胃肠道肿瘤 CAR T 细胞治疗的新希望 https://news.medxy.ai/vi/ethical-challenges-pediatrics/Medxy AIvi2026-08-30T08:29:31-07:00Vượt Qua Thách Thức Đạo Đức Trong Nội Tiết Nhi Khoa: Tiếp Cận Theo Ca Bệnh và Các Nguyên Tắc https://news.medxy.ai/ja/car-t-therapy-pancreatic-cancer/Medxy AIja2026-08-30T08:29:29-07:00CA19-9糖鎖を標的とする新規CAR T細胞療法：膵癌・消化器癌への有望なアプローチ https://news.medxy.ai/vi/car-t-therapy-pancreatic-cancer-2/Medxy AIvi2026-08-30T08:29:04-07:00Nhắm trúng glycan CA19-9: Liệu pháp tế bào T CAR đầy triển vọng cho ung thư tụy và ung thư đường tiêu hóa https://news.medxy.ai/zh/rnf213-r4810k-mutation/Medxy AIzh2026-08-30T08:27:26-07:00RNF213 p.R4810K 变异：颅外颈动脉疾病的新型独立遗传危险因素 https://news.medxy.ai/ja/rnf213-mutation-risk/Medxy AIja2026-08-30T08:27:05-07:00RNF213 p.R4810K変異：頭蓋外頸動脈疾患における新たな独立遺伝的リスク因子 https://news.medxy.ai/vi/rnf213-risk-factor/Medxy AIvi2026-08-30T08:26:43-07:00RNF213 p.R4810K: Yếu tố nguy cơ di truyền độc lập mới đối với bệnh động mạch cảnh ngoài sọ https://news.medxy.ai/zh/white-matter-lesions/Medxy AIzh2026-08-30T08:25:43-07:00揭开白质高信号的面纱：不同病灶亚型提示的临床意义远超病灶位置 https://news.medxy.ai/ja/white-matter-lesions-2/Medxy AIja2026-08-30T08:25:24-07:00白質高信号域を読み解く：病変サブタイプが示す、部位を超えた多面的臨床意義 https://news.medxy.ai/vi/white-matter-signals/Medxy AIvi2026-08-30T08:25:03-07:00Giải mã tăng tín hiệu chất trắng: Các phân nhóm tổn thương riêng biệt hé lộ ý nghĩa lâm sàng đa dạng vượt ra ngoài vị trí https://news.medxy.ai/zh/pediatric-stroke-thrombolysis/Medxy AIzh2026-08-30T08:24:48-07:00儿童急性缺血性卒中溶栓适应证：现状、局限与未来方向 https://news.medxy.ai/zh/parsonage-turner-syndrome/Medxy AIzh2026-08-30T08:24:04-07:00重症帕森奇-特纳综合征与创伤性臂丛神经病变：运动恢复与治疗结局的比较 https://news.medxy.ai/ja/severe-personage-turner-syndrome/Medxy AIja2026-08-30T08:23:43-07:00重症パーソネージ・ターナー症候群と外傷性腕神経叢障害：運動回復と治療転帰の比較 https://news.medxy.ai/vi/68899-2/Medxy AIvi2026-08-30T08:23:19-07:00Hội chứng Parsonage-Turner thể nặng và chấn thương đám rối cánh tay do sang chấn: So sánh khả năng phục hồi vận động và kết quả điều trị https://news.medxy.ai/zh/68896-2/Medxy AIzh2026-08-30T08:22:10-07:00进一步细化不确定性甲状腺结节的风险分层：Afirma Xpression Atlas 异常状态的作用 https://news.medxy.ai/ja/afirma-thyroid-risk/Medxy AIja2026-08-30T08:21:47-07:00不確定性甲状腺結節のリスク層別化をさらに洗練する：Afirma Xpression Atlas異常ステータスの役割 https://news.medxy.ai/vi/thyroid-risk-stratification/Medxy AIvi2026-08-30T08:21:24-07:00Tinh chỉnh phân tầng nguy cơ ở nhân tuyến giáp chưa xác định: Vai trò của trạng thái biến đổi Afirma Xpression Atlas https://news.medxy.ai/zh/rotavirus-vaccine-type1-diabetes/Medxy AIzh2026-08-30T08:20:22-07:00轮状病毒疫苗与1型糖尿病发病：来自挪威人群自然实验的启示 https://news.medxy.ai/ja/rotavirus-vaccine-type-1-diabetes/Medxy AIja2026-08-30T08:19:59-07:00ロタウイルスワクチンと1型糖尿病発症：ノルウェーの集団ベース自然実験から見えたこと https://news.medxy.ai/vi/rotavirus-vaccine-type-1-diabetes-2/Medxy AIvi2026-08-30T08:19:34-07:00Vắc-xin rotavirus và tỷ lệ mắc đái tháo đường týp 1: Góc nhìn từ một thí nghiệm tự nhiên dựa trên quần thể tại Na Uy https://news.medxy.ai/zh/primary-aldosteronism-diagnosis/Medxy AIzh2026-08-30T08:18:26-07:00原发性醛固酮增多症诊断再提升：LC-MS/MS 与免疫测定在尿醛固酮检测中的比较 https://news.medxy.ai/ja/primary-aldosteronism-diagnosis-3/Medxy AIja2026-08-30T08:18:07-07:00原発性アルドステロン症の診断精度を高める：尿中アルドステロン測定におけるLC-MS/MSと免疫測定法の比較 https://news.medxy.ai/vi/primary-aldosteronism-diagnosis-2/Medxy AIvi2026-08-30T08:17:43-07:00Nâng cao chẩn đoán cường aldosteron nguyên phát: So sánh LC-MS/MS và miễn dịch xét nghiệm trong đo aldosterone niệu https://news.medxy.ai/zh/semaglutide-vs-surgery-masld/Medxy AIzh2026-08-30T08:16:39-07:00司美格鲁肽与减重手术对肥胖合并MASLD患者肝脂肪变性和纤维化的比较：谁更优？ https://news.medxy.ai/ja/semaglutide-vs-surgery-masld-2/Medxy AIja2026-08-30T08:16:15-07:00MASLDを伴う肥満患者におけるセマグルチドと減量手術の肝脂肪化・線維化への影響比較 https://news.medxy.ai/vi/semaglutide-bariatric-surgery/Medxy AIvi2026-08-30T08:15:49-07:00Semaglutide và phẫu thuật giảm béo: tác động so sánh lên gan nhiễm mỡ và xơ hóa ở bệnh nhân béo phì mắc MASLD https://news.medxy.ai/zh/dash4d-diabetes-impact/Medxy AIzh2026-08-30T08:14:50-07:00DASH4D饮食对2型糖尿病成人血糖生物标志物的影响：随机对照喂养试验的研究发现 https://news.medxy.ai/ja/dash4d-diet-effects/Medxy AIja2026-08-30T08:14:33-07:002型糖尿病におけるDASH4D食の血糖指標への影響：ランダム化比較給餌試験から得られた知見 https://news.medxy.ai/vi/dash-diet-biomarkers/Medxy AIvi2026-08-30T08:14:14-07:00Chế độ ăn DASH4D cải thiện dấu ấn sinh học đường huyết ở người lớn mắc đái tháo đường type 2: Góc nhìn từ một thử nghiệm nuôi ăn ngẫu nhiên có đối chứng https://news.medxy.ai/zh/optimize-ketone-testing/Medxy AIzh2026-08-30T08:13:18-07:00优化毛细血管血酮检测频率：预测1型糖尿病短期DKA风险 https://news.medxy.ai/ja/dka-risk-prediction/Medxy AIja2026-08-30T08:12:56-07:001型糖尿病における短期DKAリスク予測のための毛細血管ケトン体測定頻度の最適化 https://news.medxy.ai/vi/optimal-ketone-testing/Medxy AIvi2026-08-30T08:12:32-07:00Tối ưu tần suất xét nghiệm ketone mao mạch để dự đoán nguy cơ nhiễm toan ceton ngắn hạn ở đái tháo đường type 1 https://news.medxy.ai/zh/ai-powered-aortic-stenosis-screening/Medxy AIzh2026-08-30T08:11:32-07:00AI赋能聚焦心脏超声：新手操作者也能高效筛查主动脉瓣狭窄 https://news.medxy.ai/ja/ai-aortic-stenosis-screening/Medxy AIja2026-08-30T08:11:14-07:00AIで変わる大動脈弁狭窄症スクリーニング：初心者でも可能にするFoCUSの新展開 https://news.medxy.ai/vi/ai-echocardiography-screening/Medxy AIvi2026-08-30T08:10:54-07:00AI và siêu âm tim khu trú: mở rộng tầm soát hẹp van động mạch chủ tới người mới thực hiện https://news.medxy.ai/zh/thyroxine-amyloid-cardiomyopathy/Medxy AIzh2026-08-30T08:09:58-07:00转甲状腺素蛋白淀粉样心肌病预后评估再升级：机器学习风险预测模型 https://news.medxy.ai/ja/68860-2/Medxy AIja2026-08-30T08:09:39-07:00トランスサイレチン型アミロイド心筋症の予後評価におけるさらなる進歩：機械学習を用いたリスク予測モデル https://news.medxy.ai/vi/amyloid-cardiomyopathy-risk/Medxy AIvi2026-08-30T08:09:19-07:00Nâng cao tiên lượng trong bệnh cơ tim amyloid transthyretin: mô hình dự đoán nguy cơ bằng machine learning https://news.medxy.ai/zh/icd-impact-mortality/Medxy AIzh2026-08-30T08:08:25-07:00心肌梗死后植入式除颤器对死亡率影响的演变：来自PROFID研究的启示 https://news.medxy.ai/ja/icd-effect-post-mi/Medxy AIja2026-08-30T08:08:05-07:00心筋梗塞後死亡率に対する植込み型除細動器の影響はどう変化したか：PROFID研究からの示唆 https://news.medxy.ai/vi/impact-automatic-implantable-defibrillator/Medxy AIvi2026-08-30T08:07:40-07:00Tác động của máy khử rung tim tự động cấy ghép đối với tử vong sau nhồi máu cơ tim: Những phát hiện từ nghiên cứu PROFID https://news.medxy.ai/ja/visualizing-gap-esc-recommendations/Medxy AIja2026-08-30T08:06:35-07:00埋められない隔たりを可視化する：ESCの予防・心臓リハビリテーション推奨と、EUROASPIRE VIが明らかにした欧州の現実 https://news.medxy.ai/vi/68850-2/Medxy AIvi2026-08-30T08:05:56-07:00Thu hẹp khoảng cách: Các khuyến nghị của ESC về phòng ngừa và phục hồi chức năng tim mạch, cùng những hiểu biết từ EUROASPIRE VI về thực trạng tại Châu Âu https://news.medxy.ai/zh/esc-prevention-cardiac-rehab/Medxy AIzh2026-08-30T08:05:23-07:00缩小差距：ESC 预防与心脏康复推荐，以及 EUROASPIRE VI 对欧洲现实的启示 https://news.medxy.ai/zh/68846-2/Medxy AIzh2026-08-30T08:03:46-07:00心力衰竭患者血红蛋白处于正常低值与临床预后的关系：重新评估世界卫生组织（WHO）贫血诊断标准 https://news.medxy.ai/ja/normal-low-hemoglobin-heart-failure/Medxy AIja2026-08-30T08:03:25-07:00心不全における正常低値ヘモグロビンと臨床転帰：WHO貧血基準の再考 https://news.medxy.ai/vi/hemoglobin-levels-heart-failure/Medxy AIvi2026-08-30T08:03:01-07:00Hemoglobin thấp-bình thường và kết cục lâm sàng trong suy tim: Cần nhìn lại các ngưỡng thiếu máu của WHO https://news.medxy.ai/zh/evolocumab-cardiovascular-protection-2/Medxy AIzh2026-08-30T08:01:42-07:00Evolocumab为无既往心肌梗死或卒中患者带来持续心血管保护：VESALIUS-CV试验解读 https://news.medxy.ai/ja/evolocumab-cardiovascular-protection/Medxy AIja2026-08-30T08:01:21-07:00MI・脳卒中既往のない患者におけるEvolocumabの持続的な心血管保護効果：VESALIUS-CV試験からの知見 https://news.medxy.ai/vi/68839-2/Medxy AIvi2026-08-30T08:01:00-07:00Evolocumab mang lại hiệu quả bảo vệ tim mạch bền vững ở bệnh nhân chưa từng bị nhồi máu cơ tim hoặc đột quỵ: Những thông tin từ thử nghiệm VESALIUS-CV https://news.medxy.ai/zh/ventricular-stiffness/Medxy AIzh2026-08-30T07:59:58-07:00Fontan 循环中低心室腔室僵硬度：高风险离心性重构的新标志——基于 FORCE 登记研究的启示 https://news.medxy.ai/ja/low-ventricular-stiffness/Medxy AIja2026-08-30T07:59:39-07:00Fontan循環における高リスク偏心的リモデリングを示す指標としての低い心室内腔硬さ https://news.medxy.ai/vi/low-ventricle-stiffness/Medxy AIvi2026-08-30T07:59:17-07:00Độ cứng buồng thất thấp: dấu ấn của tái cấu trúc lệch tâm nguy cơ cao trong tuần hoàn Fontan từ FORCE Registry https://news.medxy.ai/zh/non-physician-led-bp-control/Medxy AIzh2026-08-30T07:58:10-07:00非医师主导的强化降压可带来持久心血管获益：CRHCP试验7年随访 https://news.medxy.ai/ja/68830-2/Medxy AIja2026-08-30T07:57:51-07:00医師以外の医療従事者が主導する強力な血圧低下療法は、持続的な心血管系への有益な効果をもたらす：CRHCP試験の7年間の追跡調査 https://news.medxy.ai/vi/68829-2/Medxy AIvi2026-08-30T07:57:27-07:00Việc tích cực hạ huyết áp dưới sự điều hành của nhân viên y tế không phải là bác sĩ mang lại lợi ích tim mạch bền vững: Kết quả theo dõi 7 năm của thử nghiệm CRHCP https://news.medxy.ai/ja/68826-2/Medxy AIja2026-08-30T07:56:20-07:00バイオシミラーの市場参入：腫瘍領域におけるバイオ医薬品の使用および支払者・患者の経済的負担への影響 https://news.medxy.ai/vi/biosimilars-impact/Medxy AIvi2026-08-30T07:55:56-07:00Biosimilars sau khi gia nhập thị trường: Tác động đến sử dụng thuốc sinh học ung thư và gánh nặng tài chính cho bên chi trả, người bệnh